Hye Hyeon Eum on Muck Rack

Hye Hyeon Eum

As seen in: Nature, eLife
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hye Hyeon

Contact Hye Hyeon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

|
By Nayoung Kim, Sehhoon Park, Areum Jo, Hye Hyeon Eum
| eLife
eLife Assessment The authors utilized single-cell RNA-seq profiling of non-small cell lung cancer (NSCLC) patient tumor samples to generate useful insights into the determinants of immune checkpoint inhibitor (ICI) responsiveness in NSCLC patients.
Open in Who Shared Issue with article?

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

|
By Nayoung Kim, Sehhoon Park, Areum Jo, Hye Hyeon Eum
| biorxiv.org
Abstract This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICI). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, it becomes crucial to identify biomarkers that influence responses to ICI therapy.
Open in Who Shared Issue with article?

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

|
By Nayoung Kim, Sehhoon Park, Areum Jo, Hye Hyeon Eum
| biorxiv.org
Abstract This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICI). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, it becomes crucial to identify biomarkers that influence responses to ICI therapy.
Open in Who Shared Issue with article?
See all 6 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified